Targeting Src in breast cancer.

The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics. Src and its family members make up the largest group of nonreceptor tyrosine kinases. In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis. In addition, Src plays an important role in osteoclast activation and bone resorption, which are often aberrantly activated in the setting of bone metastases. Given its role in these functions, blocking Src kinase would be predicted to have a broad therapeutic benefit in patients with Src-dependent cancers. In this review, we highlight the rationale for targeting Src in breast cancer, including laboratory and clinical data implicating it in these signaling pathways, and review small-molecule tyrosine kinase inhibitors currently in clinical development. Identifying which patients should be selected for Src-directed therapies will be important to the clinical success of these agents. Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options.

[1]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[2]  R. Jove,et al.  Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. , 2006, Cancer research.

[3]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[4]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[5]  R. Tootell,et al.  Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor , 2005 .

[6]  R. Roskoski,et al.  Src kinase regulation by phosphorylation and dephosphorylation. , 2005, Biochemical and biophysical research communications.

[7]  W. Gradishar,et al.  Gene expression in breast cancer , 2006, Current treatment options in oncology.

[8]  S. Parsons,et al.  Characterization of human epidermal growth factor receptor and c‐Src interactions in human breast tumor cells , 1998, Molecular carcinogenesis.

[9]  D. Bowtell,et al.  Cbl Associates with Pyk2 and Src to Regulate Src Kinase Activity, αvβ3 Integrin-Mediated Signaling, Cell Adhesion, and Osteoclast Motility , 2001, The Journal of cell biology.

[10]  Silvia Bernardini,et al.  Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation , 2000, The Journal of cell biology.

[11]  J. M. García-Martínez,et al.  Role of c-Src in Human MCF7 Breast Cancer Cell Tumorigenesis* , 2006, Journal of Biological Chemistry.

[12]  Alan Cantor,et al.  Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression , 2006, Clinical Cancer Research.

[13]  Paul J. Williams,et al.  C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. , 2003, Cancer research.

[14]  P. Ji,et al.  Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[16]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[17]  D. Yu,et al.  Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors , 2006, Oncogene.

[18]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[19]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[21]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.

[22]  T. Miyake,et al.  c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function , 2007, Oncogene.

[23]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[24]  M. Zimmer,et al.  EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. , 2002, Molecular cell.

[25]  Paul Workman,et al.  Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[26]  V. Jordan,et al.  Steroid receptors and their role in the biology and control of breast cancer growth. , 2006, Seminars in oncology.

[27]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[28]  D. Mukhopadhyay,et al.  Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. , 2001, Cancer research.

[29]  D. Edwards,et al.  Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. , 2004, Essays in biochemistry.

[30]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[31]  M. Maa,et al.  Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Fuqua,et al.  Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor–positive human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[33]  Fei Ye,et al.  SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. , 2005, Cancer research.

[34]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[35]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[36]  D. Drucker,et al.  Parathyroid hormone-related peptide is a downstream target for ras and src activation. , 1994, The Journal of biological chemistry.

[37]  C. Vogel,et al.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.

[38]  W. Muller,et al.  c-Src-null mice exhibit defects in normal mammary gland development and ERα signaling , 2005, Oncogene.

[39]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[40]  L. Luttrell,et al.  Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src , 1988, Molecular and cellular biology.

[41]  D. Fujita,et al.  Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells , 2002, BMC Biochemistry.

[42]  P. Altevogt,et al.  Role of Src Kinases in the ADAM-mediated Release of L1 Adhesion Molecule from Human Tumor Cells* , 2000, The Journal of Biological Chemistry.

[43]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[44]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[45]  R. Eastell,et al.  The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males , 2005 .

[46]  S. Rabbani,et al.  A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.

[47]  D. Holt,et al.  A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. , 2000, Chemistry & biology.

[48]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[49]  Yi Zhang,et al.  Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  F. Lee,et al.  Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. , 2006, The American journal of pathology.

[51]  R. Nicholson,et al.  Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.

[52]  J. Parsons,et al.  pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src , 1989, Molecular and cellular biology.

[53]  R. Nicholson,et al.  Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells , 2007, Clinical & Experimental Metastasis.

[54]  E. Avizienyte,et al.  Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. , 2005, Current opinion in cell biology.

[55]  T. Yoneda,et al.  Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.

[56]  P. Yaciuk,et al.  Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[57]  F. Lee,et al.  BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo , 2005 .

[58]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[59]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.

[60]  H. Rugo,et al.  Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) , 2005 .

[61]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Monilola A. Olayioye,et al.  ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.

[63]  N. Hynes,et al.  An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. , 2001, Experimental cell research.

[64]  M. Shupnik Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation , 2004, Oncogene.

[65]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[66]  G. Rijksen,et al.  c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS , 1996, The Journal of pathology.

[67]  N. Tokudome,et al.  Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways , 2007, Breast cancer.

[68]  H. Rübsamen,et al.  Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. , 1983, Cancer research.